Evaluation of Rapid Sepsityper® protocol and specific MBT-Sepsityper module (Bruker Daltonics) for the rapid diagnosis of bacteremia and fungemia by MALDI-TOF-MS.

Publisher: BioMed Central Country of Publication: England NLM ID: 101152152 Publication Model: Electronic Cited Medium: Internet ISSN: 1476-0711 (Electronic) Linking ISSN: 14760711 NLM ISO Abbreviation: Ann Clin Microbiol Antimicrob Subsets: MEDLINE

Original Publication: London : BioMed Central, [2002]-

Bacteremia/*diagnosis ; Bacteria/*isolation & purification ; Bacterial Typing Techniques/*methods ; Fungemia/*diagnosis ; Mycological Typing Techniques/*methods ; Tandem Mass Spectrometry/*methods ; Yeasts/*isolation & purification; Bacteremia/microbiology ; Bacteria/chemistry ; Blood/microbiology ; Blood Culture ; Fungemia/microbiology ; Humans ; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization/methods ; Yeasts/chemistry

During bloodstream infections, rapid adaptation of empirical treatment according to the microorganism identified is essential to decrease mortality. The aim of the present study was to assess the microbiological performances of a new rapid version of the Sepsityper® kit (Bruker Daltonics) allowing identification of bacteria and yeast by MALDI-TOF mass spectrometry directly from positive blood cultures in 10 min and of the specific MBT-Sepsityper module for spectra analysis, designed to increase identification performance. Identification rates were determined prospectively on 350 bacterial and 29 fungal positive blood cultures, and compared to conventional diagnostic method. Our rapid diagnosis strategy (Rapid Sepsityper® protocol: one spot with and one without formic acid extraction step) combined to MBT-Sepsityper module provided 65.4%, 78.9% and 62% reliable identification to the species level of monomicrobial positive blood cultures growing respectively Gram-positive, Gram-negative bacteria or yeast. Importantly, identification rates of Gram-positive bacteria were higher in anaerobic than in aerobic bottles (77.8% vs 22.2%; p = 0.004), if formic acid extraction step was performed (60.8% vs 39.2%; p = 1.8e ^-6 ) and if specific MBT-Sepsityper module was used (76.2% vs 61.9%, p = 0.041) while no significant differences were observed for Gram-negative bacteria. For yeasts identification, formic acid extraction step improved rapid identification rate by 37.9% while the specific MBT-Sepsityper module increased overall performances by 38%, providing up to 89.7% reliable identification if associated with the standard Sepsityper® protocol. These performances, associated with a reduce turnaround time, may help to implement a rapid identification strategy of bloodstream infections in the routine workflow of microbiology laboratories.

Diagn Microbiol Infect Dis. 2018 Nov;92(3):189-193. (PMID: 30122510)
Mycoses. 2014 Oct;57(10):592-601. (PMID: 24862948)
Clin Infect Dis. 2009 May 15;48 Suppl 4:S238-45. (PMID: 19374579)
J Clin Microbiol. 2019 Jan 30;57(2):. (PMID: 30463897)
J R Coll Physicians Edinb. 2018 Jun;48(2):114-119. (PMID: 29992199)
J Appl Microbiol. 2014 Apr;116(4):934-41. (PMID: 24410849)
J Clin Microbiol. 2015 May;53(5):1761-4. (PMID: 25762771)
Clin Infect Dis. 2013 Apr;56(8):1101-7. (PMID: 23264363)
Antimicrob Agents Chemother. 2012 Jan;56(1):472-8. (PMID: 22005999)
BMC Res Notes. 2017 Jan 18;10(1):48. (PMID: 28100271)
Eur J Clin Microbiol Infect Dis. 2012 Jul;31(7):1353-8. (PMID: 22037773)
J Antimicrob Chemother. 2018 Mar 1;73(suppl_4):iv20-iv26. (PMID: 29608753)
J Clin Microbiol. 2016 Mar;54(3):687-98. (PMID: 26739158)
Eur J Clin Microbiol Infect Dis. 2011 Sep;30(9):1127-34. (PMID: 21373774)
Rev Esp Quimioter. 2018 Jun;31(3):263-267. (PMID: 29756430)
J Microbiol Methods. 2015 Feb;109:157-9. (PMID: 25541363)
J Infect Dev Ctries. 2013 Sep 16;7(9):670-5. (PMID: 24042103)
Med Mal Infect. 2016 Jun;46(4):194-9. (PMID: 27132208)
J Clin Microbiol. 2014 Mar;52(3):924-30. (PMID: 24403301)
J Infect. 2010 Oct;61(4):335-42. (PMID: 20637801)
Ann Fr Anesth Reanim. 2005 Mar;24(3):315-22. (PMID: 15792575)
Clin Infect Dis. 2013 Nov;57(9):1237-45. (PMID: 23899684)
Wien Klin Wochenschr. 2017 Jun;129(11-12):427-434. (PMID: 28243751)
Expert Rev Mol Diagn. 2018 Feb;18(2):119-132. (PMID: 29284316)
Int J Microbiol. 2015;2015:827416. (PMID: 26000017)
J Fungi (Basel). 2018 Apr 04;4(2):. (PMID: 29617284)
Diagn Microbiol Infect Dis. 2012 May;73(1):21-6. (PMID: 22578935)
Clin Infect Dis. 2006 Jul 1;43(1):25-31. (PMID: 16758414)
Crit Care Med. 2015 Oct;43(10):2258-9. (PMID: 26376254)
Clin Microbiol Infect. 2013 Jun;19(6):501-9. (PMID: 23473333)
J Clin Microbiol. 2017 Dec 26;56(1):. (PMID: 29118168)
Curr Microbiol. 2017 Jan;74(1):97-102. (PMID: 27858149)
Clin Microbiol Infect. 2018 Sep;24(9):935-943. (PMID: 29605563)
J Microbiol Methods. 2017 Aug;139:54-60. (PMID: 28461023)
Enferm Infecc Microbiol Clin. 2019 May;37(5):319-323. (PMID: 30072283)
Intern Med J. 2014 Dec;44(12b):1315-32. (PMID: 25482743)
Clin Infect Dis. 2016 Nov 15;63(10):1332-1339. (PMID: 27558570)
FEMS Microbiol Rev. 2012 Mar;36(2):380-407. (PMID: 22092265)
J Microbiol Methods. 2018 Dec;155:1-7. (PMID: 30442592)
J Clin Lab Anal. 2020 Apr;34(4):e23119. (PMID: 31724218)
Int J Infect Dis. 2016 Nov;52:37-42. (PMID: 27658644)
PLoS One. 2016 Oct 31;11(10):e0165346. (PMID: 27798663)
J Clin Microbiol. 2010 Apr;48(4):1481-3. (PMID: 20164269)
J Antimicrob Chemother. 2006 Nov;58(5):1082-5. (PMID: 16950822)
Crit Care Nurs Clin North Am. 2011 Mar;23(1):79-97. (PMID: 21316569)
J Med Microbiol. 2015 Nov;64(11):1346-1352. (PMID: 26361761)
Med Mycol. 2017 Feb 1;55(2):185-192. (PMID: 27281814)
Eur J Clin Microbiol Infect Dis. 2018 Nov;37(11):2145-2152. (PMID: 30128666)
Clin Microbiol Infect. 2010 Nov;16(11):1631-8. (PMID: 20825442)
Infect Dis (Lond). 2019 Apr;51(4):249-258. (PMID: 30729840)
Eur J Clin Microbiol Infect Dis. 2018 Jul;37(7):1333-1344. (PMID: 29700761)
Intensive Care Med. 2013 Feb;39(2):165-228. (PMID: 23361625)
Front Cell Infect Microbiol. 2019 Oct 22;9:361. (PMID: 31696061)
BMC Infect Dis. 2014 Nov 28;14:489. (PMID: 25431091)
Crit Care Med. 2011 Aug;39(8):1886-95. (PMID: 21516036)
Antimicrob Agents Chemother. 2005 Sep;49(9):3640-5. (PMID: 16127033)
Diagn Microbiol Infect Dis. 2015 Nov;83(3):216-8. (PMID: 26256418)
Diagn Microbiol Infect Dis. 2013 Aug;76(4):404-8. (PMID: 23726652)
J Clin Microbiol. 2014 Jul;52(7):2521-9. (PMID: 24808235)
Microbiol Spectr. 2016 Apr;4(2):. (PMID: 27227291)
Acta Clin Belg. 2015 Oct;70(5):325-30. (PMID: 25946409)
J Clin Microbiol. 2010 May;48(5):1584-91. (PMID: 20237093)
Indian J Med Microbiol. 2012 Jul-Sep;30(3):270-8. (PMID: 22885191)
Curr Infect Dis Rep. 2015 Jul;17(7):493. (PMID: 26031965)
J Clin Microbiol. 2013 Mar;51(3):805-9. (PMID: 23254131)
BMC Infect Dis. 2019 Jan 18;19(1):72. (PMID: 30658585)
Proteomics Clin Appl. 2017 May;11(5-6):. (PMID: 27921389)
J Clin Microbiol. 2013 Dec;51(12):4130-6. (PMID: 24088863)
Intensive Care Med. 2014 Jan;40(1):32-40. (PMID: 24026297)
Scand J Infect Dis. 2013 Sep;45(9):664-71. (PMID: 23808723)
Med Mycol. 2020 Jul 1;58(5):639-649. (PMID: 31579924)
PLoS One. 2017 Nov 17;12(11):e0187990. (PMID: 29149187)
J Microbiol Methods. 2018 May;148:138-144. (PMID: 29656124)
Dan Med J. 2015 Jul;62(7):. (PMID: 26183054)
Clin Microbiol Infect. 2013 Jun;19(6):492-500. (PMID: 23398633)
J Clin Microbiol. 2019 Jan 30;57(2):. (PMID: 30487304)
Curr Med Res Opin. 2013 Apr;29 Suppl 4:13-8. (PMID: 23621589)
Chest. 2009 Nov;136(5):1237-1248. (PMID: 19696123)
J Antimicrob Chemother. 2014 Aug;69(8):2132-6. (PMID: 24722840)
J Infect Chemother. 2019 May;25(5):341-345. (PMID: 30718191)

Keywords: Bacteremia; Blood culture; Fungemia; MALDI-TOF mass spectrometry; Rapid identification; Sepsis; Sepsityper®

Date Created: 20201210 Date Completed: 20210902 Latest Revision: 20210902

20240829

PMC7727196

10.1186/s12941-020-00403-w

33298064